1st patient treated in Qilu's China Phase 2 trial of LSTA1 with metastatic pancreatic ductal adenocarcinoma, in combination with standard chemotherapy.

Lisata Therapeutics and Qilu Pharmaceutical announce the first patient treated in Qilu's Phase 2 trial in China evaluating LSTA1 in patients with metastatic pancreatic ductal adenocarcinoma. LSTA1, Lisata's lead product candidate, is being tested in combination with standard-of-care chemotherapy. The announcement follows positive results from Phase 1b/2 in China, reinforcing global clinical development plans for LSTA1.